Here is the rundown on market activity for Opko Health, Inc. (NASDAQ:OPK). Yesterday Director Robert A. Baron disclosed the sale of 37,500 shares of OPK stock. The shares were sold on May 13th for an average price of $9.83. The Director now owns $2,792,585 of the stock according to the SEC filing. Executive VP-Administration Steven D. Rubin acquired 1,000 shares at an average price of $10.17 on Wed the 30th. Rubin now owns $55,349,279 of stock as recorded in a recent Form 4 SEC filing.
Today Jane Ph D. Hsiao, Vice Chairman & CTO disclosed the purchase of 3,600 shares of (OPK). The shares sold for $9.91. Hsiao now owns $243,732,813 of the stock per the Form 4 SEC filing.
The following firms have also recently changed their position in OPK. As of the end of the quarter Williams Jones & Associates LLC had acquired 8,800 shares growing its holdings by 352.0%. The value of the total investment in Opko Health, Inc. increased from $26,000 to $106,000 increasing 307.7% since the last quarter. As of quarter end Northwestern Mutual Wealth Management Co had bought a total of 23 shares growing its stake by 0.9%. The value of the investment in OPK went from $28,000 to $25,000 a change of 10.7% for the reporting period.
As of quarter end Wolverine Asset Management LLC had acquired 1,148,681 shares growing its position 8,891.4%. The value of the company’s investment in Opko Health, Inc. went from $5,791,000 to $10,849,000 a change of $5,058,000 quarter over quarter. As of quarter end Royal Bank Of Canada had acquired 1,712 shares growing its position 594.4%. The value in dollars went from $3,000 to $19,000 a change of $16,000 quarter to quarter.
Standpoint Research began coverage of the stock setting a rating of “Buy”. On March 31 Barrington Research maintained a company rating of “Outperform” and lowered the price expectation from $17.00 to $16.00.
Equity analyst JP Morgan starting coverage on OPK with a rating of “Overweight” and a price target of $14.00. On August 12 analysts at Laidlaw & Co issued its first research report on the stock with an initial rating of “Buy” and establishing a price target of $22.00.
On March 26, 2015 Barrington Research began coverage by announcing an initial rating of “Outperform” and setting a price target of $19.00. On March 3, 2015 the stock rating was changed to a “Perform” according to a Oppenheimer report a cut from the previous “Outperform” rating.
The company is so far trading down from yesterday’s close of $11.19. Shares last traded at $10.87 slightly over the 50 day moving average of $9.95 and a bit higher than the 200 day moving average of $10.12. The 50 day moving average went up by +9.19% and the 200 day average moved up $0.75.
Opko Health, Inc. currently has a P/E ratio of 45.48 and the market value is 5.98B. In the latest earnings report the EPS was $0.24 and is estimated to be $-0.05 for the current year with 550,380,000 shares presently outstanding. Analysts expect next quarter’s EPS to be $-0.03 and the next full year EPS is anticipated to be $0.03.
Traders are feeling more bullish on shares of Opko Health, Inc. of late if you pay attention to the motion in short interest. The company realized a fall in short interest from August 31, 2016 to September 15, 2016 of -0.01%. Short interest decreased from 69,651,044 to 69,139,269 over that timeframe. The short-interest ratio decreased to 18.1 and the percentage of shorted shares was 0.13% on September 15.